Azacitidine ± Lenalidomide or Vorinostat (higher-risk MDS/CMML)
Current understanding
Randomized phase II/III trial (trial-late evidence) evaluating whether the addition of lenalidomide (an immunomodulatory imide drug) or vorinostat (an HDAC inhibitor) to azacitidine improves outcomes versus azacitidine monotherapy in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia. Relevant to the MPN area through the CMML/MDS-MPN overlap subgroup. Tests combination strategies layered on the established hypomethylating agent backbone.
Evidence log
- 2026-05-29 — Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia: cross-connection with azacitidine-venetoclax-cmml: Both trials evaluate azacitidine-based combinations in higher-risk CMML; lenalidomide/vorinostat add-on versus venetoclax add-on represent alternative strategies layered on the same HMA backbone. (novelty: 3)
Open questions
Related
Contributing findings
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
29-may-2026
novelty 3
per-area 3
introduces